<DOC>
	<DOC>NCT00892840</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of BMS-820836 after multiple doses</brief_summary>
	<brief_title>Multiple-Ascending Dose Study</brief_title>
	<detailed_description />
	<criteria>Panels 16: Healthy Male Subjects Panel 7: Females Ages 21 to 55, inclusive Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations Any major surgery within 4 weeks of study drug administration History of cholecystectomy History of glaucoma or a confirmed intraocular pressure indicative of glaucoma at screening. (Normal IOP &lt;21 mmHg) Confirmed QTc (Fridericia) value ≥ 450 msec Confirmed QT ≥ 500 msec Confirmed PR ≥ 210 msec Confirmed QRS ≥ 120 msec Confirmed resting supine systolic blood pressure &gt; 140 mmHg Confirmed resting supine diastolic blood pressure &gt; 90 mmHg Confirmed resting heart rate &lt; 45 bpm or &gt; 100 bpm Orthostatic vital sign changes (ie., a decrease in systolic blood pressure from supine to standing &gt; 40 mmHg and an increase in heart rate from supine to standing &gt; 20 bpm) or symptoms of orthostasis History of peppermint allergies Exposure to any investigational drug or placebo within 12 weeks of study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>